Highlights
- •Thrombosis is a major problem in patients with high grade glioblastoma tumors (GBM).
- •We investigated several potential thrombosis risk factors in 139 GBM patients.
- •B blood group but not A or O blood groups significantly increased thrombosis risk.
- •GBM patients with B blood group could benefit from thrombosis prophylaxis.
Abstract
Introduction
Venous thromboembolism (VTE) is a common problem among patients with glioblastoma
multiforme (GBM) and with some other cancers. Here, we evaluated genetic and non-genetic
potential risk factors for VTE among GBM patients.
Materials and methods
A cohort of 139 patients treated with concomitant radiotherapy and temozolomide were
included in the study. Next generation sequencing and genotyping approaches were applied
to assess genetic risk factors in the haemostatic system. Clinical data including
surgery, reoperation as well as blood group and patient information such as age and
gender were available from patient records. Logistic regression analysis was performed
to asses VTE risk.
Results
In the study 47 patients (34%) were diagnosed for VTE during the course of their disease.
When genetic and non-genetic potential risk factors were evaluated, only B blood group
was found to be significantly associated with VTE incidence (odds ratio [OR] = 6.91;
confidence interval [CI] = 2.19–24.14; P = 0.001). In contrast, A and O blood groups did not correlate with VTE risk. Frontal
lobe tumor location also seemed to slightly increase VTE risk compared to other brain
sites (OR = 3.14; CI = 1.1–10.7) although the significance level was at borderline
(P = 0.05). Current study identified B blood group as the component in non-O blood groups
that is responsible for increased VTE risk.
Conclusion
In conclusion, these results suggest for the first time that B blood group is predictive
for VTE incidence among patients with glioblastoma, information that may be potentially
valuable when selecting GBM patients who are at risk for VTE for anticoagulant prophylaxis.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Genetic pathways linking hemostasis and cancer.Thromb Res. 2012; 129: S22-S29
- Venous thrombosis and cancer: from mouse models to clinical trials.J Thromb Haemost. 2015; 13: 1372-1382
- Epidemiology of cancer-related venous thromboembolism.Best Pract Res Clin Haematol. 2009; 22: 9-23
- Venous Thromboembolism in Brain Tumor Patients.Adv Exp Med Biol. 2017; 906: 215-228
- Thromboembolic disease in patients with high-grade glioma.Neuro Oncol. 2012; 14: iv73-80
- Brain neoplasms and coagulation.Semin Thromb Hemost. 2013; 39: 881-895
- Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.Eur J Cancer. 1997; 33: 1592-1596
- Venous thromboembolism (VTE) and glioblastoma.J Neurooncol. 2015; 124: 87-94
- In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease.Nat Med. 1996; 2: 209-215
- Thrombin receptor overexpression in malignant and physiological invasion processes.Nat Med. 1998; 4: 909-914
- The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.Protein J. 2015; 34: 338-348
- Mechanisms and risk factors of thrombosis in cancer.Crit Rev Oncol Hematol. 2017; 118: 79-83
- Venous thromboembolism and survival in patients with high-grade glioma.Neuro Oncol. 2007; 9: 89-95
- Epidemiology of cancer-associated venous thrombosis.Blood. 2013; 122: 1712-1723
- Mutation in blood coagulation factor V associated with resistance to activated protein C.Nature. 1994; 369: 64-67
- A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.Blood. 1996; 88: 3698-3703
- Causes of venous thrombosis.Thrombosis Journal. 2016; 14: 24
- Malignancies, prothrombotic mutations, and the risk of venous thrombosis.JAMA. 2005; 293: 715-722
- The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis.Ann Hematol. 2009; 88: 73-76
- Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.J Natl Cancer Inst. 2010; 102: 942-949
- Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients.Br J Haematol. 2005; 128: 386-388
- Association of deep venous thrombosis with prothrombotic gene polymorphism identified in lung cancer cases.Mol Biol Rep. 2011; 38: 2395-2400
- Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.Ann Oncol. 2010; 21: 871-876
- Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).J Thromb Haemost. 2015; 13: 17-22
- Non-O blood group: an important genetic risk factor for venous thromboembolism.Blood Transfus. 2013; 11: 164-165
- ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden.J Thromb Haemost. 2005; 3: 183-185
- Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach.Blood. 2009; 113: 5298-5303
- ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors.Circulation. 2016; 133 (discussion 1457): 1449-1457
- Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.Oncol Lett. 2017; 14: 3787-3794
- von Willebrand Factor and Venous Thromboembolism: pathogenic Link and Therapeutic Implications.Semin Thromb Hemost. 2018; 44: 249-260
- factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level.American Journal of Human Genetics. 1985; 37: 89-101
- Genetic variations associated with recurrent venous thrombosis.Circulation. Cardiovascular Genetics. 2014; 7: 806-813
- The Sequence Alignment/Map format and SAMtools.Bioinformatics. 2009; 25: 2078-2079
- R Foundation for Statistical Computing.(Vienna, Austria)https://www.R-project.org/Date: 2016
- Factor V Leiden paradox in a middle-aged Swedish population: a prospective study.Vasc Med. 2018; 23: 52-59
- ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas.Cancer. 2004; 100: 1717-1723
- Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis.Thromb Res. 2003; 109: 171-174
- Are factor V and prothrombin mutations associated with increased risk of oral cancer?.Anticancer Res. 2005; 25: 2561-2565
- Risk of prostate cancer and thrombosis-related factor polymorphisms.Biomed Rep. 2014; 2: 53-56
- Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.Ann Oncol. 2004; 15: 590-593
- Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.J Thromb Thrombolysis. 2007; 23: 31-34
- Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma.Cancer. 2002; 94: 3120-3126
- Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment.Acta Neurochir (Wien). 2018; 160: 1779-1787
- Association between supratotal glioblastoma resection and patient survival: a systematic review and meta-analysis.World Neurosurg. 2019; 127 (Epub 2019 Apr 17): 617-624https://doi.org/10.1016/j.wneu.2019.04.092
- Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013.Neuro Oncol. 2019; : 360-369https://doi.org/10.1093/neuonc/noy195
- Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature.Semin Thromb Hemost. 2012; 38: 535-548
- Beyond immunohaematology: the role of the ABO blood group in human diseases.Blood Transfus. 2013; 11: 491-499
- ABO blood groups and cancer of the pancreas.Int J Pancreatol. 1990; 6: 81-88
Article info
Publication history
Published online: October 22, 2019
Accepted:
October 14,
2019
Received in revised form:
September 23,
2019
Received:
June 20,
2019
Identification
Copyright
© 2019 Elsevier Ltd. All rights reserved.
